The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial
Armand P, Kim HT, Sainvil M, et al.
Key Points:
Sirolimus benefit in the prevention and treatment of GVHD after allogeneic hematopoietic stem cell transplantation (HSCT) investigated in this phase III trial of patients undergoing RIC HSCT
Cumulative incidence of grade 2-4 acute GVHD significantly lower with sirolimus-containing regimen (tacrolimus, sirolimus and methotrexate) compared with conventional sirolimus-free regimens (tacrolimus + methotrexate or cyclosporine + MMF)
chronic GVHD rates similar between the groups
No difference in OS
Implications:
Sirolimus-containing regimen represent an effective anti-GVHD regimen in recipients of RIC HSCT using T-cell-replete peripheral blood stem cells
View the original abstract on the ASH website.
